ARA-290

ARA-290’s mechanism is rooted in a fundamentally new understanding of how tissues protect themselves from damage — one that repositions erythropoietin from a simple blood-building hormone to a master orchestrator of tissue repair.

The Two-Receptor Model of EPO Signaling

For decades, erythropoietin’s only recognized function was stimulating red blood cell production through the EPO receptor (EPOR) homodimer on erythroid progenitor cells. Clinical experience with recombinant EPO demonstrated tissue-protective properties as well, but these came bundled with dangerous side effects: elevated hematocrit, platelet activation, and increased risk of thrombosis and stroke. The key discovery was that EPO signals through an entirely separate receptor complex for tissue protection — a heterodimer composed of one EPOR subunit and one β-common receptor (βCR, also called CD131) subunit. This heterodimer, termed the Innate Repair Receptor (IRR), has critically distinct biology:

• It is not expressed on normal, healthy tissue — instead it is rapidly induced by injury, hypoxia, oxidative stress, or inflammation
• It does not respond to erythropoietic EPO concentrations — it requires higher local concentrations, which are generated by stressed and injured cells themselves​
• It is expressed broadly throughout the body — in neurons, cardiomyocytes, endothelial cells, macrophages, pancreatic β-cells, dermal fibroblasts, and the spinal cord
• It serves as a molecular sentinel: remaining silent during health and activating precisely when and where tissue injury occurs

ARA-290 was designed as a selective IRR agonist that activates tissue protection without touching the EPOR homodimer — and its non-overlapping receptor specificity has been confirmed in multiple studies showing zero effect on hematocrit, hemoglobin, or erythropoiesis.

Downstream Signaling Pathways

Upon IRR activation, ARA-290 initiates a coordinated cascade of protective cellular responses:

• JAK2-STAT3/STAT5 pathway: IRR engagement activates Janus kinase 2 (JAK2), which phosphorylates and activates STAT3 and STAT5, transcription factors that drive expression of anti-inflammatory and cytoprotective genes
• PI3K/Akt prosurvival pathway: Activation of phosphoinositide-3 kinase and Akt suppresses apoptotic signaling, protecting injured cells from programmed cell death
• NF-κB suppression: ARA-290 reduces nuclear factor-kappa B activity, decreasing production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6
• TRPV1 channel blockade: Cibinetide blocks peripheral nociceptors — specifically transient receptor potential vanilloid-1 (TRPV1) ion channels — which directly alleviates mechanical hypersensitivity and neuropathic pain independent of its anti-inflammatory actions​

Neuroprotection and Neural Regeneration

ARA-290’s effects in neural tissue involve both protection of existing fibers and active promotion of new nerve fiber growth:

• Microglia modulation: Following peripheral nerve injury, ARA-290 prevents the spread of microglial activation from the primary injury site in the spinal cord to adjacent segments — blocking a mechanism that would otherwise drive expanding chronic neuroinflammation​
• CCL2 reduction: ARA-290 reduces release of CCL2 (monocyte chemoattractant protein-1) from neuronal and immune cells, limiting recruitment of additional immune cells to the injury zone​
• Neurite outgrowth: Activation of the IRR directly promotes axon sprouting and small nerve fiber regeneration, as quantifiably demonstrated through corneal nerve fiber density measurements in clinical trials
• Sympathetic ganglia protection: ARA-290 was shown to reverse pathological neuropathic changes in sympathetic ganglia in diabetic animal models, explaining improvements in autonomic symptoms (dry eyes, orthostatic hypotension) seen in sarcoidosis patients​

Pancreatic β-Cell Protection

In diabetic models, ARA-290 improves pancreatic β-cell function through a distinct mechanism involving mitochondrial metabolism:​

• ARA-290 increases β-cell glucose oxidation and ATP production through the Krebs cycle, improving the ATP/ADP ratio that drives insulin secretion
• This enhanced metabolism triggers KATP channel closure, membrane depolarization, and L-type Ca²⁺ channel opening — the core pathway for glucose-stimulated insulin secretion
• ARA-290 also activates PKA-dependent amplification pathways, augmenting insulin secretion 2.7-fold in hyperglycemic conditions compared to glucose alone
• Critically, ARA-290 does not cause insulin secretion at basal glucose levels — its effects are glucose-dependent, eliminating hypoglycemia risk​

The “Molecular Switch” Concept

A striking pharmacological feature of ARA-290 is that despite an extremely short plasma half-life of approximately 2 minutes, it produces sustained biological effects lasting days to weeks. This suggests that IRR activation functions as a molecular switch — triggering downstream epigenetic and transcriptional reprogramming that outlasts the compound’s physical presence. The initial IRR signal appears to shift cellular programming from a pro-inflammatory, pro-apoptotic state to an anti-inflammatory, pro-repair state in a sustained, self-perpetuating manner.

ARA-290 has accumulated an unusually robust body of human clinical evidence for an unapproved peptide, including multiple randomized controlled trials across distinct patient populations.

Phase 2a: Sarcoidosis Small Fiber Neuropathy — IV Dosing (2012–2013)

The first human trial was a double-blind, placebo-controlled pilot study in 22 sarcoidosis patients with confirmed small fiber neuropathy (SFN) symptoms, receiving intravenous ARA-290 (2 mg) or placebo three times per week for 4 weeks:​

• ARA-290 produced significant improvement in the Small Fiber Neuropathy Symptom List (SFNSL) score at week 4 versus placebo (Δ −11.5 ± 3.04 vs. Δ −2.9 ± 3.34; P < 0.05)
• Significant improvements in the pain and physical functioning dimensions of the SF-36 quality of life questionnaire
• Notable improvement in autonomic symptoms including dry eyes, blurred vision, and orthostatic symptoms
• No drug-related adverse effects and no abnormalities in laboratory or clinical evaluations
• First human study to confirm ARA-290 is safe with repeated intravenous administration​

Phase 2a: Sarcoidosis SFN — Subcutaneous Dosing (2013–2014)

A second Phase 2a study evaluated daily subcutaneous ARA-290 in sarcoidosis patients with documented small nerve fiber loss and density (SNFLD) for 28 days:

• Significant improvement in neuropathic symptom scores and physical functioning
• Critically, corneal nerve fiber density (CNFD) measurably increased compared to placebo — providing objective, quantifiable evidence of actual nerve fiber regeneration, not just symptom relief
• Improved cutaneous temperature sensitivity
• Improved exercise capacity on the 6-minute walk test
• No hematocrit increase, confirming absence of erythropoietic activity

This was the first study to demonstrate a disease-modifying effect — physical regrowth of nerve fibers — rather than purely symptomatic benefit.

Phase 2: Type 2 Diabetes with Neuropathy (2014–2015)

A Phase 2 randomized trial evaluated subcutaneous ARA-290 (4 mg daily for 28 days) in patients with type 2 diabetes and painful neuropathy:

• No potential safety issues identified
• Subjects receiving ARA-290 showed improvement in HbA1c (glycated hemoglobin — a marker of long-term blood glucose control) and improved lipid profiles throughout the 56-day observation period
• Neuropathic symptoms assessed by the PainDetect questionnaire improved significantly in the ARA-290 group
• In subjects with mean CNFD more than 1 standard deviation below normal, ARA-290 produced a significant increase in corneal nerve fiber density vs. no change in placebo
• Consistent with animal data showing direct β-cell metabolic improvement​

Phase 2b: Sarcoidosis SFN — Dose-Finding Study (NCT02039687)

The definitive Phase 2b study enrolled 64 subjects with sarcoidosis-associated small nerve fiber loss and neuropathic pain in a randomized, double-blind, placebo-controlled trial comparing cibinetide 1 mg, 4 mg, and 8 mg daily for 28 days:

• 4 mg/day was identified as the optimal dose: produced a placebo-corrected mean increase in corneal nerve fiber area (CNFA) of 697 μm² (P = 0.012)
• GAP-43-positive (regenerating) intraepidermal nerve fibers increased 23% in the 4 mg group (P = 0.035)
• CNFA changes correlated strongly with 6-minute walk test improvements (Spearman ρ = 0.645; P = 0.009) — linking nerve regeneration directly to functional recovery
• Pain improved in all treatment groups; subjects with moderate-to-severe pain in the 4 mg group showed clinically meaningful placebo-corrected pain reduction
• Adverse events were mild (fatigue, nausea, diarrhea) with no serious events

Phase 2: Diabetic Macular Edema (2020)

A Phase 2 trial evaluated subcutaneous cibinetide for diabetic macular edema over 12 weeks:​

• The 12-week course was safe — no serious adverse events or anti-cibinetide antibodies were detected
• Some participants experienced improvements in central retinal thickness (CRT), tear production, diabetic control, and albuminuria
• Results “warrant further investigation” in a larger, powered trial​

Preclinical Anti-Aging Research

Research at the National Institute on Aging (NIA) presented at the Experimental Biology meeting (2018) showed that ARA-290 treatment in rats from 18 to 33 months of age significantly slowed age-related decline in heart function, improved ejection fraction, reduced frailty scores, and extended healthspan in aging animals — opening a potential application in the biology of aging.​

Additional Preclinical Findings

ARA-290 has demonstrated efficacy across a broad range of preclinical models:

• Burn injury: Maintained microvascular patency, mitigated TNF-α signaling, and reduced secondary thrombosis in deep partial-thickness cutaneous burns​
• Renal ischemia-reperfusion: Reduced plasma creatinine, urea, and AST — markers of kidney dysfunction — in rodent models​
• Neuropathic pain: Reduced tactile allodynia in spinal nerve injury models, with effects shown to be entirely absent in mice lacking the β-common receptor, confirming IRR specificity
• Experimental autoimmune neuritis: Improved recovery, enhanced nerve regeneration and remyelination, suppressed nerve inflammation​
• Chemotherapy protection: Attenuated doxorubicin-induced genotoxicity, oxidative stress, and DNA damage in HepG2, HGF, and stem cell lines; protected against cisplatin-induced nephrotoxicity
• Cerebral ischemic stroke: Demonstrated brain tissue protection through the β-common receptor in a mouse MCAO model, with reduced infarct volume and improved neurological outcomes​

Traumatic brain injury: Reduced latency to find the platform in Morris water maze testing after cortical impact in rats

Clinical Development and Orphan Designations

ARA-290 has advanced through multiple Phase 2 trials and holds significant regulatory designations:

• FDA Orphan Drug Designation for Sarcoidosis-Associated Small Fiber Neuropathy: Granted in 2014, recognizing ARA-290 as a promising therapy for this rare, difficult-to-treat condition​
• FDA Orphan Drug Designation for Pancreatic Islet Transplantation: A fourth orphan designation was obtained in July 2016 for the use of ARA-290 to increase survival and improve functioning of transplanted pancreatic islets — addressing a critical challenge in Type 1 diabetes treatment​
• NCT02039687 (Phase 2b, Sarcoidosis SFN): The definitive Phase 2b dose-finding study (64 subjects, 28 days, Leiden University Medical Center and Cleveland Clinic), identifying 4 mg/day subcutaneous as the optimal dose with corneal nerve fiber regrowth as the primary endpoint. Published in Investigative Ophthalmology & Visual Science (2017)​
• Phase 2 Diabetic Macular Edema Trial (EudraCT 2015-001940-12; ISRCTN16962255): 12-week subcutaneous cibinetide course confirming safety; published 2020​
• Phase 3 Trials: Multiple Phase 3 trials are reportedly underway as of 2025–2026, with potential regulatory pathways being explored for accelerated approval. Araim Pharmaceuticals has maintained a clinical development partnership with Vault Bioventures since 2016.

Regulatory Status

ARA-290/cibinetide is not currently approved for therapeutic use by any regulatory agency.

• FDA (United States): ARA-290 is not listed in the FDA’s Category 2 bulk drug substances for compounding (the restricted list that includes BPC-157, DSIP, GHRP-6, and CJC-1295). This is a meaningful distinction — ARA-290 has not been placed on the FDA’s list of compounds presenting “significant safety risks” for compounding. Its active clinical development program and orphan drug designations give it a different regulatory posture from most peptides in the research market.
• WADA: ARA-290/cibinetide is not currently listed on the 2025 or 2026 WADA Prohibited Lists. Unlike GHRP-6 and CJC-1295, which directly stimulate GH release and carry obvious performance-enhancement potential, ARA-290’s mechanism (tissue repair via the IRR) does not provide a recognized performance-enhancing effect, making it a lower anti-doping priority.
• EU/EMA: No marketing authorization. Active European clinical development has been conducted through Leiden University Medical Center and collaborating centers, with EudraCT registrations.​

ARA-290 has one of the cleanest safety profiles among all clinically studied peptides, characterized by an almost complete absence of adverse events across all human studies:

Confirmed Absent Effects

• No hematocrit increase: In all human studies, hemoglobin and hematocrit values were unchanged in ARA-290 recipients versus placebo — definitively confirming the absence of erythropoietic activity
• No anti-drug antibodies: No anti-cibinetide antibodies were detected in any clinical study, including the 12-week diabetic macular edema trial​
• No thrombotic events: No venous thromboembolism, pulmonary embolism, stroke, or cardiovascular events attributed to ARA-290 in any clinical study
• No platelet activation: Unlike recombinant EPO, ARA-290 does not activate platelets or upregulate selectin expression​
• No serious adverse events: Across all published Phase 2 trials, no serious adverse events attributed to ARA-290 were reported
• No hypoglycemia: In diabetic subjects, ARA-290’s glucose-dependent mechanism of insulin augmentation produced metabolic improvement without hypoglycemia

Mild Reported Side Effects

• Fatigue, nausea, and mild diarrhea were reported in the Phase 2b sarcoidosis trial across treatment groups; these were mild and did not lead to discontinuation​
• No injection site reactions of clinical significance were reported with subcutaneous dosing​

Pharmacokinetics

• Plasma half-life of approximately 2 minutes after subcutaneous injection, followed by degradation to component amino acids​
• The extremely short half-life means systemic exposure is minimal and transient
• Despite this brief presence in circulation, biological effects are sustained for days to weeks due to IRR-mediated molecular reprogramming​
• No accumulation or dose-dependent toxicity reported​

Important Limitations

• The longest published human exposure data is 12 weeks (the diabetic macular edema trial); no long-term safety data (>3 months) has been published​
• The total number of humans who have received ARA-290 across all published trials is approximately 150–200 subjects
• No formal reproductive toxicity, mutagenicity, or carcinogenicity studies have been published in the open literature
• The reported Phase 3 activity has not yet resulted in published safety or efficacy data

1. Brines, M., et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.
2. Swartjes, M., et al. (2015). Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.
3. Leist, M., et al. (2004). Derivatives of erythropoietin that are tissue protective but not erythropoietic.
4. Dahan, A., et al. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
5. Heij, L., et al. (2012). Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study.
6. Culver, D.A., et al. (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.
7. Swartjes, M., et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
8. Brines, M., et al. (2014). ARA 290, a peptide derived from the tertiary structure of erythropoietin, acts as a skewed agonist of the erythropoietin receptor/β common receptor heterodimer.
9. Dahan, A., et al. (2016). Targeting the innate repair receptor to treat neuropathy.
10. Brines, M. & Cerami, A. (2012). The Receptor That Tames the Innate Immune Response.
11. Erbayraktar, Z., et al. (2009). Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing.
12. Jonsson Fagerlind, M., et al. (2015). ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats.
13. Erbayraktar, S., et al. (2013). Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns.
14. Erythropoietin-Derived Nonerythropoietic Peptide Ameliorates Experimental Autoimmune Neuritis. (2014).
15. Bajorunas, D., et al. (2020). A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema
16. Chen, C., et al. (2024). Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke.
17. National Institute on Aging. (2018). Cibinetide Significantly Reduces Frailty and Decline in Heart Function Associated with Aging in Animal Models.
18. IUPHAR/BPS Guide to Pharmacology.
19. ClinicalTrials.gov. NCT02039687: Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Sarcoidosis.
20. Araim Pharmaceuticals Inc.